Jade Biosciences (JBIO) Oppenheimer 36th Annual Healthcare Life Sciences Conference summary

Strategic overview and pipeline

• Focus on developing best-in-class therapeutics for autoimmune diseases using high-affinity monoclonal antibodies and half-life extension technology from Paragon Therapeutics.

• Three main programs: JADE101 (anti-APRIL for IgA nephropathy), JADE201 (anti-BAFF-R for autoimmune diseases), and JADE301 (target undisclosed, clinic entry planned for 1H 2027).

• Strong financial position with $336 million in cash at end of 2025, funding operations into 1H 2028.

• Team has proven expertise in IgA nephropathy and related fields.

Lead program: JADE101 for IgA nephropathy

• JADE101 aims to be best-in-class, leveraging femtomolar potency and YTE half-life extension for superior efficacy and convenience.

• Phase I healthy volunteer trial readout expected in 1H this year, with Phase II initiation planned mid-2026 and interim data in 2027.

• IgA nephropathy market estimated at $10B+ in the US, with recent approvals expanding the eligible patient population.

• New KDIGO guidelines and biomarker targets are expected to drive adoption of highly efficacious anti-APRIL therapies.

• JADE101 designed for dosing no more frequent than every 8 weeks, aiming for high patient convenience.

Competitive positioning and clinical rationale

• Anti-APRIL class is expected to become frontline therapy for IgA nephropathy due to disease-modifying potential.

• JADE101 is over 750-fold more potent than sibeprenlimab and aims to capture full efficacy left untapped by current competitors.

• Preclinical data show extended half-life and deeper, prolonged IgA reduction compared to competitors.

• Healthy volunteer biomarker data are highly predictive of patient outcomes, supporting rapid clinical advancement.